Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3659-3665. doi: 10.1007/s00259-023-06331-z. Epub 2023 Jul 17.
Soluble epoxide hydrolase (sEH) is an enzyme that shapes immune signaling through its role in maintaining the homeostasis of polyunsaturated fatty acids and their related byproducts. [F]FNDP is a radiotracer developed for use with positron emission tomography (PET) to image sEH, which has been applied to imaging sEH in the brains of healthy individuals. Here, we report the test-retest repeatability of [F]FNDP brain PET binding and [F]FNDP whole-body dosimetry in healthy individuals.
Seven healthy adults (4 men, 3 women, ages 40.1 ± 4.6 years) completed [F]FNDP brain PET on two occasions within a period of 14 days in a test-retest study design. [F]FNDP regional total distribution volume (V) values were derived from modeling time-activity data with a metabolite-corrected arterial input function. Test-retest variability, mean absolute deviation, and intraclass correlation coefficient (ICC) were investigated. Six other healthy adults (3 men, 3 women, ages 46.0 ± 7.0 years) underwent [F]FNDP PET/CT for whole-body dosimetry, which was acquired over 4.5 h, starting immediately after radiotracer administration. Organ-absorbed doses and the effective dose were then estimated.
The mean test-retest difference in regional V (ΔV) was 0.82 ± 5.17%. The mean absolute difference in regional V was 4.01 ± 3.33%. The ICC across different brain regions ranged from 0.92 to 0.99. The organs with the greatest radiation-absorbed doses included the gallbladder (0.081 ± 0.024 mSv/MBq), followed by liver (0.077 ± 0.018 mSv/MBq) and kidneys (0.063 ± 0.006 mSv/MBq). The effective dose was 0.020 ± 0.003 mSv/MBq.
These data support a favorable test-retest repeatability of [F]FNDP brain PET regional V. The radiation dose to humans from each [F]FNDP PET scan is similar to that of other F-based PET radiotracers.
可溶性环氧化物水解酶（sEH）是一种通过维持多不饱和脂肪酸及其相关代谢产物的内稳态来调节免疫信号的酶。[F]FNDP 是一种为正电子发射断层扫描（PET）成像而开发的示踪剂，用于成像健康个体大脑中的 sEH。在这里，我们报告了健康个体中 [F]FNDP 脑 PET 结合和 [F]FNDP 全身剂量测定的复测重复性。
在一项测试-复测研究设计中，7 名健康成年人（4 名男性，3 名女性，年龄 40.1±4.6 岁）在 14 天内完成了两次 [F]FNDP 脑 PET。使用代谢校正的动脉输入函数对时间-活性数据进行建模，得出 [F]FNDP 区域总分布容积（V）值。研究了复测变异性、平均绝对偏差和组内相关系数（ICC）。另外 6 名健康成年人（3 名男性，3 名女性，年龄 46.0±7.0 岁）接受了 [F]FNDP PET/CT 全身剂量测定，在放射性示踪剂给药后立即开始，持续 4.5 小时。然后估计器官吸收剂量和有效剂量。
区域 V（ΔV）的平均复测差异为 0.82±5.17%。区域 V 的平均绝对差异为 4.01±3.33%。不同脑区的 ICC 范围为 0.92 至 0.99。吸收剂量最大的器官包括胆囊（0.081±0.024 mSv/MBq），其次是肝脏（0.077±0.018 mSv/MBq）和肾脏（0.063±0.006 mSv/MBq）。有效剂量为 0.020±0.003 mSv/MBq。
这些数据支持 [F]FNDP 脑 PET 区域 V 的良好复测重复性。每次 [F]FNDP PET 扫描对人体的辐射剂量与其他基于 F 的 PET 示踪剂相似。
